Heartbeam rises after FDA clears its cable‑free ECG software

Heartbeam

10/12/2025 13:05

** Shares of heart monitor maker Heartbeam BEAT.O soar 67.6% to $1.34 premarket

** HeartBeam says the U.S. FDA has cleared its software that lets a small, cable‑free device record a detailed heart rhythm test at home, overturning an earlier rejection

** The software turns signals from HeartBeam's credit‑card sized gadget into a 12‑lead electrocardiogram (ECG), the same format doctors use in clinics and hospitals to study heart rhythm

** A reading taken by the patient is sent for review to an on‑call heart specialist, the company says

** BEAT plans a limited U.S. launch in early 2026 with a small group of concierge and preventive cardiology practices that have already shown interest

** As of last close, BEAT stock was down ~65% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))